

Pietro Francia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7327407/pietro-francia-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

608
citations

14
h-index

23
g-index

54
ext. papers

765
ext. citations

3.5
avg, IF

3.19
L-index

#	Paper	IF	Citations
49	The "Defibrillation Testing, Why Not?" survey. Testing of subcutaneous and transvenous defibrillators in the Italian clinical practice.. <i>IJC Heart and Vasculature</i> , 2022 , 38, 100952	2.4	0
48	Longevity of model-3501 subcutaneous implantable defibrillator leads in clinical practice. Viani: Longevity of S-ICD leads.. <i>Heart Rhythm</i> , 2022 ,	6.7	0
47	Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: a Propensity-Matched Case-Control Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , CIRCEP121010381	6.4	1
46	Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
45	Acute shock efficacy of the subcutaneous implantable cardioverter-defibrillator according to the implantation technique. <i>Journal of Cardiovascular Electrophysiology</i> , 2021 , 32, 1695-1703	2.7	0
44	Role of induced pluripotent stem cells in diagnostic cardiology. <i>World Journal of Stem Cells</i> , 2021 , 13, 331-341	5.6	0
43	Multi-Modality Imaging Approach in a Challenging Case of Surgically Corrected Partial Anomalous Pulmonary Venous Return and Atrial Tachycardia Treated With Radiofrequency Ablation. <i>Cureus</i> , 2021 , 13, e13009	1.2	1
42	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 703418	5.4	0
41	Prognostic implications of nonsustained ventricular tachycardia morphology in high-risk patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2093-2098	2.7	0
40	Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 291-297	2.9	0
39	Assessing Atrial Fibrillation Substrates by P Wave Analysis: A Comprehensive Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 341-347	2.9	3
38	Implantation technique and optimal subcutaneous defibrillator chest position: a PRAETORIAN score-based study. <i>Europace</i> , 2020 , 22, 1822-1829	3.9	6
37	Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: Results from an Italian multicenter registry. <i>International Journal of Cardiology</i> , 2019 , 280, 74-79	3.2	12
36	Time to therapy delivery and effectiveness of the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2019 , 16, 1531-1537	6.7	6
35	Ventricular fibrillation undersensing due to air entrapment in a patient implanted with a subcutaneous cardioverter defibrillator. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 1373-1374	2.7	2
34	The subcutaneous implantable cardioverter-defibrillator: Current trends in clinical practice between guidelines and technology progress. <i>European Journal of Internal Medicine</i> , 2019 , 65, 6-11	3.9	1
33	Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019 , 42, 610-616	1.6	2

32	Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018 , 52, 61-67	2.4	17
31	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018 , 11, e005820	6.4	26
30	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. <i>Revista Portuguesa De Cardiologia</i> , 2018 , 37, 351.e1-351.e4	1	1
29	Subcutaneous implantable cardioverter defibrillator implantation: An analysis of Italian clinical practice and its evolution. <i>International Journal of Cardiology</i> , 2018 , 272, 162-167	3.2	16
28	Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	8
27	Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 633-642	1.9	4
26	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018 , 122, 1924-1931	3	11
25	The effects of gender on electrical therapies for the heart: procedural considerations, results and complications: A report from the XII Congress of the Italian Association on Arrhythmology and Cardiac Stimulation (AIAC). <i>Europace</i> , 2017 , 19, 1911-1921	3.9	3
24	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017 , 248, 326-332	3.2	18
23	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2017 , 28, 103-108	2.7	14
22	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	13
21	Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. <i>International Journal of Cardiology</i> , 2016 , 221, 881-5	3.2	2
20	Calcium channel blockers and hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015 , 20, 121-30	2.6	20
19	P-wave duration in lead aVR and the risk of atrial fibrillation in hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2015 , 20, 167-74	1.5	13
18	Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 893-899	2.7	40
17	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 656-61	2.7	2
16	A Novel Electrocardiographic T-Wave Measurement (Tp-Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for First-Line Electrocardiographic Evaluation. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 441-9	2.3	12
15	Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2014 , 25, 609-16	2.7	23

14	Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. <i>ISRN Cardiology</i> , 2014 , 2014, 652421		4
13	Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2014 , 25, 1180-7	2.7	19
12	New oral anticoagulants in non-valvular atrial fibrillation. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013 , 20, 53-60	2.9	3
11	Common genetic variants in selected Ca ²⁺ signaling genes and the risk of appropriate ICD interventions in patients with heart failure. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013 , 38, 169-77	2.4	9
10	Atrial natriuretic Peptide single nucleotide polymorphisms in patients with nonfamilial structural atrial fibrillation. <i>Clinical Medicine Insights: Cardiology</i> , 2013 , 7, 153-9	3.2	4
9	Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. <i>International Journal of Cardiology</i> , 2011 , 153, 306-10	3.2	27
8	p66(Shc) protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. <i>Journal of Molecular Medicine</i> , 2009 , 87, 885-91	5.5	43
7	Arrhythmia detection in single- and dual-chamber implantable cardioverter defibrillators: the more leads, the better?. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 1077-82	2.7	21
6	Extracellular matrix remodelling in myocardial hypertrophy and failure : focus on osteopontin. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009 , 16, 195-9	2.9	5
5	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 17-22	2.9	1
4	Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. <i>Journal of Cardiovascular Electrophysiology</i> , 2008 , 19, 457-62	2.7	78
3	Left bundle-branch block--pathophysiology, prognosis, and clinical management. <i>Clinical Cardiology</i> , 2007 , 30, 110-5	3.3	49
2	Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. <i>European Journal of Heart Failure</i> , 2007 , 9, 306-9	12.3	63
1	Oxidative Stress and Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003 , 10, 27-33	2.9	